Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 16, 2021

Moderna starts Phase I study of new Covid-19 vaccine candidate

American pharmaceutical and biotechnology company Moderna has started an early-stage study of a new Covid-19 vaccine candidate.

American pharmaceutical and biotechnology company Moderna has started an early-stage study of a new Covid-19 vaccine candidate.

The company has dosed the first patients in the Phase I study of mRNA-1283, which is being developed as a potential refrigerator stable mRNA vaccine to enable easier distribution.

The study will evaluate the safety and immunogenicity of mRNA-1283 at three dose levels.

The vaccine candidate will be administered at 10µg, 30µg, and 100µg doses on healthy adults as a two-dose series with a gap of 28 days, as well as one dose at 100µg.

The results will be compared with the currently authorised two-dose series of 100µg of mRNA-1273.

Moderna CEO Stéphane Bancel said: “We are pleased to begin this Phase I study of our next generation Covid-19 vaccine candidate, mRNA-1283.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

“Our investments in our mRNA platform have enabled us to develop this next generation vaccine candidate, which is a potential refrigerator-stable vaccine that could facilitate easier distribution and administration in a wider range of settings, including potentially for developing countries.”

mRNA-1283 encodes for the portions of the SARS-CoV-2 spike protein critical for neutralisation, specifically the Receptor Binding Domain (RBD) and N-terminal Domain (NTD).

In future, the company plans to test the efficacy of mRNA-1283 for use as a booster dose for previously vaccinated as well as seropositive individuals.

Last week, Moderna began dosing the first subjects in a study assessing its Covid-19 booster vaccine candidates. Subjects are being enrolled by amending the ongoing Phase II clinical study.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy